Kuratsu S, Tomita Y, Myoui A, Uchida A, Ono K, Aozasa K
Department of Pathology, Osaka University, Japan.
Oncology. 1995 Sep-Oct;52(5):363-70. doi: 10.1159/000227490.
Staining and counting of argyrophilic nucleolar organizer region (AgNOR), segments of DNA with ribosomal genes, is useful for estimation of the proliferative activity in soft tissue sarcoma (STS). The precise role of AgNOR in STS, however, is still uncertain. In the present study, ploidy pattern and stage of cell cycle were analyzed in 151 cases of STS in the extremities and trunk, and their correlation with AgNOR and utility as independent prognostic factors were estimated. For this, microspectrophotometric and flow-cytometric analyses were done on paraffin-embedded material from 84 and 111 cases, respectively. Fifty-five percent cases showed an aneuploid pattern with a less favorable prognosis. The range of the DNA index and percentage of cells in S + G2M phase were 0.89-2.04 (mean +/- SD, 1.23 +/- 0.32) and 5.4-83.7% (mean +/- SD, 32.95 +/- 17.92), respectively. Tumors having less than 40% cells in the S + G2M phase showed a favorable prognosis compared to those over 40%. Both the ploidy pattern and stage of the cell cycle showed a good correlation with the AgNOR count: a high frequency of cases having aneuploidy and S + G2M phase in the AgNOR high count group. These findings provide a theoretical base for explaining the utility of AgNOR for the estimation of proliferative activity. In multivariate analysis, only AgNOR counts were a prognostic factor among histologic factors reflecting proliferative activity of tumors. The DNA ploidy pattern and the stage of the cell cycle was proved not to be an independent factor for prognosis.
嗜银核仁组织区（AgNOR）是带有核糖体基因的DNA片段，对其进行染色和计数有助于评估软组织肉瘤（STS）的增殖活性。然而，AgNOR在STS中的确切作用仍不明确。在本研究中，对151例四肢和躯干的STS病例进行了倍体模式和细胞周期阶段分析，并评估了它们与AgNOR的相关性以及作为独立预后因素的效用。为此，分别对84例和111例石蜡包埋材料进行了显微分光光度法和流式细胞术分析。55%的病例显示非整倍体模式，预后较差。DNA指数范围和S + G2M期细胞百分比分别为0.89 - 2.04（平均值±标准差，1.23±0.32）和5.4 - 83.7%（平均值±标准差，32.95±17.92）。与S + G2M期细胞超过40%的肿瘤相比，S + G2M期细胞少于40%的肿瘤预后良好。倍体模式和细胞周期阶段均与AgNOR计数显示出良好的相关性：在AgNOR高计数组中，非整倍体和S + G2M期的病例频率较高。这些发现为解释AgNOR在评估增殖活性方面的效用提供了理论基础。在多变量分析中，在反映肿瘤增殖活性的组织学因素中，只有AgNOR计数是一个预后因素。DNA倍体模式和细胞周期阶段被证明不是预后的独立因素。
